TCJL-37 is a potent TYK2 inhibitor.

Oclacitinib is a potent JAK inhibitor with IC50 value ranging in 10-99 nM for JAK family members, most potent against JAK1 with IC50 value of 10 nM.

WHI-P258 is a quinazoline compound that binds to the active site of JAK3 with an estimated Ki of 72 µM, but does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM[1][2].

Cerdulatinib HCl is a dual JAK/SYK inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. It also inhibits other kinases with IC50 less than 200 nM.

WHI-P97 is a rationally designed potent inhibitor of JAK-3.

FM381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909 at the gatekeeper position +7 in JAK3. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.

GDC046 was an effective and selective oral biouse inhibitor of TYK2, with Ki values of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM against TYK2, JAK1, JAK2 and JAK3, respectively.

NVP-BSK805 is a selective JAK2 and JAK2(V617F) mutant inhibitor with IC50 value of 0.48 nM, with >20-fold selectivity over TYK2, JAK3 and JAK1 (IC50 values of 10.8, 18.7 and 31.6 nM, respectively).

Solcitinib is a highly selective JAK1 inhibitor with IC50 value of 9.8 nM, with much less potency against JAK1 and JAK2 with IC50 values >100nM.

JANEX-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (IC50 = 78 μM) and has no effect on JAK1, JAK2, or Zap/Syk or SRC tyrosine kinases.

S-Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, > 130-fold selectivity for JAK1/2 versus JAK3.

Pyridone 6 is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM) displaying significantly weaker affinities(130 nM to 10 mM) for other protein tyrosine kinases.

Upadacitinib is a selective JAK1 inhibitor with an IC50 of 43 nM.

PF-06826647 is a selective TYK2 inhibitor It is being tested in moderate-to-severe psoriasis in a Phase II clinical trial.

Baricitinib Phosphate can selectively inhibit JAK1/2 inhibitor with IC50 values of 5.9 nM and 5.7 nM.

CEP-33779 is a highly selective JAK2 inhibitor with IC50 value of 1.8 nM, with much less potency against JAK1 and TYK2 with >40- and >800-fold IC50 values.

NS-018 maleate is an ATP-competitive small-molecule inhibitor of JAK2 with IC50 of 470?nM in Ba/F3-JAK2V617F cells .

JAK3-IN-6 is an irreversible, potent and highly selective JAK3 inhibitor with IC50 value of 0.15 nM, 4300-fold selective for JAK3 over JAK1 in enzyme assays.

GLPG0634 analog is a pan JAK inhibitor with IC50s of 50-200 nM for JAK1/JAK2/JAK3.

JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.